CON Financials: Revenue Breakdown, Margins & Competitor Comparison
This article provides a financial overview of Concentra Group Holdings Parent Inc (CON), detailing its revenue breakdown, profitability margins, and a comparison with competitors. The company primarily generates revenue from occupational health centers, with "Workers compensation" being the largest contributor. CON maintains a gross margin of 22.34% and has a market capitalization of $2.68B, facing competition from companies like LFST and BLLN.
Vanguard disaggregates holdings; CON shows 0 shares (CON)
Vanguard Group has filed an amended Schedule 13G/A report for Concentra Group Holdings Parent Inc (CON), indicating they now hold 0 shares (0%) of the common stock. This change is due to an internal realignment within Vanguard, effective January 12, 2026, where certain subsidiaries will report beneficial ownership separately, in accordance with SEC Release No. 34-39538. Ashley Grim, Head of Global Fund Administration, signed the filing on March 26, 2026, confirming that Vanguard no longer beneficially owns these disaggregated securities.
CON PE Ratio & Valuation, Is CON Overvalued
Concentra Group Holdings Parent Inc (CON) is currently considered undervalued based on its forward PE ratio of 13.50 compared to its five-year average of 16.24. The fair price for CON is estimated between $71.64 to $76.70 against a current price of $21.67, indicating it is undervalued by 69.75%. Despite having a P/S ratio above the industry average, its strong revenue growth might not sustain this premium.
Concentra Group Holdings Parent, Inc. Sees Revision in Stock Evaluation Amid Market Dynamics
Concentra Group Holdings Parent, Inc. has undergone a stock evaluation revision, with its shares currently priced at $21.91. The company has shown volatility, outperforming the S&P 500 year-to-date with an 11.33% return, but lagging over the past year. Technical indicators present a mixed outlook, with some bullish signs on a weekly basis and mildly bearish signals from OBV and Dow Theory.
JPMorgan Chase & Co. Increases Position in Concentra Group Holdings Parent, Inc. $CON
JPMorgan Chase & Co. increased its stake in Concentra Group Holdings Parent, Inc. (NYSE:CON) by 13% in the third quarter, now owning 3.02% of the company valued at $81.09 million. Concentra recently beat analyst expectations with $0.28 EPS and $539.08 million in revenue, and pays a quarterly dividend. The stock holds a "Moderate Buy" consensus rating with an average target price of $30.00.
Concentra outlines $2.25B–$2.35B 2026 revenue target while expanding de novo and M&A strategy
Concentra has set an ambitious revenue target of $2.25 billion to $2.35 billion for 2026, driven by an aggressive expansion strategy. The company plans to open 25-30 de novo locations and acquire 10-15 centers annually. This growth is expected to boost its market share in the $34 billion occupational health sector.
Ghisallo Capital Management LLC Cuts Position in Concentra Group Holdings Parent, Inc. $CON
Ghisallo Capital Management LLC reduced its stake in Concentra Group Holdings Parent, Inc. (NYSE:CON) by one-third, selling 50,000 shares to hold 100,000 shares valued at $2.09 million. Despite this reduction, several other large institutions like Thrivent Financial and Envestnet significantly increased their positions. The company recently reported strong quarterly earnings, beating EPS estimates, and announced a quarterly dividend.
Barrow Hanley Mewhinney & Strauss LLC Invests $35.12 Million in Concentra Group Holdings Parent, Inc. $CON
Barrow Hanley Mewhinney & Strauss LLC has invested approximately $35.12 million in Concentra Group Holdings Parent, Inc. by purchasing 1,678,179 shares, representing about 1.31% of the company. Other institutional investors have also adjusted their holdings in CON. The company's stock is up 0.1%, and it recently declared a quarterly dividend of $0.0625.
Latest CON News - Select Medical Holdings Corporation Announce...
This page provides the latest news and analysis for Concentra Group Holdings Parent, Inc. (CON), a major player in U.S. occupational health. Recent updates include a special stock distribution by Select Medical Holdings, Concentra's strong Q3 2024 financial results, and expansions of its medical centers in various U.S. cities. The company continues to grow its network, enhance its services, and evolve its operations within the occupational health sector.
Concentra Group Holdings Parent, Inc. (NYSE:CON) Given Average Recommendation of "Moderate Buy" by Analysts
Concentra Group Holdings Parent, Inc. (NYSE:CON) has received a "Moderate Buy" average rating from five brokerages, with an average 12-month price target of $30.00. The company recently reported strong Q4 earnings, beating estimates with $0.28 EPS and revenues up 15.9% year-over-year. Institutional investors have significantly increased their stakes in CON, while the company also announced a quarterly dividend.
Cramer Rosenthal Mcglynn LLC Has $43.77 Million Position in Concentra Group Holdings Parent, Inc. $CON
Cramer Rosenthal Mcglynn LLC significantly increased its stake in Concentra Group Holdings Parent, Inc. ($CON), making it the firm's sixth-largest holding with a value of $43.77 million. Concentra has shown strong financial performance, beating quarterly earnings expectations with 15.9% year-over-year revenue growth. Analysts maintain a "Moderate Buy" rating for CON, with an average price target of $30.00, following recent target upgrades and positive ratings.
Analysts Offer Insights on Healthcare Companies: Amneal Pharmaceuticals (AMRX), Concentra Group Holdings Parent, Inc. (CON) and Opus Genetics (IRD)
Healthcare sector analysts have issued bullish ratings for Amneal Pharmaceuticals (AMRX), Concentra Group Holdings Parent, Inc. (CON), and Opus Genetics (IRD). J.P. Morgan's Chris Schott maintained a Buy rating for Amneal Pharmaceuticals with an $18.00 price target. Mizuho Securities' Ann Hynes reiterated a Buy rating for Concentra Group Holdings Parent, Inc. with a $28.00 price target, and JonesTrading's Debanjana Chatterjee maintained a Buy rating for Opus Genetics with a $10.00 price target, with all three companies showing significant upside potential based on current analyst consensus.
Royce & Associates LP Acquires 80,714 Shares of Concentra Group Holdings Parent, Inc. $CON
Royce & Associates LP increased its stake in Concentra Group Holdings Parent (NYSE:CON) by 23.7% in the third quarter, purchasing 80,714 additional shares to own a total of 421,560 shares valued at approximately $8.82 million. This represents about 0.33% of the company. Concentra Group Holdings Parent recently reported strong quarterly earnings, beating EPS estimates, and declared a $0.0625 quarterly dividend.
Concentra Group Holdings Parent (CON) Stock Analysis: 20% Upside Potential with Strong Buy Ratings
Concentra Group Holdings Parent (CON) is presented as an attractive investment in the healthcare sector, boasting a $3.04 billion market cap and strong 15.90% revenue growth. With a significant Return on Equity of 48.07% and a forward P/E of 14.30, the company shows solid profitability and future growth prospects. Analysts have issued 7 buy ratings with an average target price of $28.57, suggesting over 20% upside potential for the stock.
Earnings Beat, Dividend Hike, and Buybacks Might Change The Case For Investing In Concentra (CON)
Concentra Group Holdings Parent (CON) recently announced a strong fourth-quarter 2025 earnings beat, including increased revenue, net income, and a cash dividend. The company plans to continue growth through smaller acquisitions and new clinic openings, supported by a new $100 million share repurchase program. While this reinforces the investment narrative of growth, investors should consider the ongoing risk of profitability pressure from integration costs and debt.
Earnings Beat, Dividend Hike, and Buybacks Might Change The Case For Investing In Concentra (CON)
Concentra Group Holdings Parent, Inc. (CON) recently announced strong Q4 2025 results with increased revenue and net income, alongside a cash dividend and a new share repurchase program. The company plans to focus on smaller bolt-on acquisitions and expand its de novo clinic pipeline. While this reinforces growth catalysts, investors should monitor the potential for margin pressure from integration costs.
Concentra Q4 2025 Earnings: $34.7M Net Income, Revenue Tops Estimates | Financial Report - News and Statistics
Concentra Group Holdings Parent Inc. (CON) announced strong financial results for the fourth quarter and full fiscal year of 2025, exceeding analyst expectations. The company reported a Q4 net income of $34.7 million (27 cents per share, 28 cents adjusted) and quarterly revenue of $539.1 million, surpassing Zacks Investment Research forecasts. For the entire fiscal year, Concentra achieved an annual profit of $166.4 million and revenue of $2.16 billion, and projects 2026 revenue between $2.25 billion and $2.35 billion.
Concentra Group Holdings Parent, Inc. Declares Cash Dividend, Payable on or About March 19, 2026
Concentra Group Holdings Parent, Inc. announced a cash dividend of $0.0625 per share. The dividend was declared on February 25, 2026, and is payable on or about March 19, 2026. Stockholders of record as of the close of business on March 12, 2026, will be eligible to receive the dividend.
Earnings call transcript: Concentra’s Q4 2025 earnings beat forecasts, stock reacts
Concentra Group Holdings Parent Inc. reported strong Q4 2025 financial results, with EPS of $0.28 and revenue of $539.1 million, both surpassing market expectations. The company saw a 15.9% year-over-year revenue increase and a 22.9% rise in Adjusted EBITDA, leading to a 0.68% uptick in premarket stock trading. Executives highlighted strategic acquisitions and organic growth as key drivers, and provided a positive outlook for 2026, including plans for record de novo openings and continued M&A in smaller deals.
Concentra Group Holdings Parent, Inc. (NYSE:CON) Declares $0.06 Quarterly Dividend
Concentra Group Holdings Parent, Inc. (NYSE:CON) has declared a quarterly dividend of $0.0625 per share, payable on March 19th to shareholders of record on March 12th. This dividend represents an annualized yield of about 1.0%. The company recently exceeded quarterly EPS estimates, reporting $0.28 against an expected $0.23, and saw its revenue increase by 15.9% year-over-year to $539.1 million.
Concentra Group Holdings Parent, Inc. SEC 10-K Report
Concentra Group Holdings Parent, Inc. (CON), the largest occupational health services provider in the U.S., has released its 2025 10-K report detailing robust financial performance and strategic initiatives. The company reported significant revenue growth and net income, driven by organic expansion and acquisitions like Nova Medical Centers and Pivot Onsite Innovations. Despite facing challenges such as economic uncertainty, labor shortages, and regulatory risks, Concentra plans continued growth through further acquisitions, service expansion, and prudent capital management.
Concentra: Overview of Fourth Quarter Financial Results
Concentra Group Holdings Parent Inc. reported strong fourth-quarter results, with net income of $34.7 million and adjusted earnings of $0.28 per share, surpassing analyst expectations. The company also exceeded revenue estimates for the quarter, generating $539.1 million. For the full year, Concentra achieved a profit of $166.4 million on $2.16 billion in revenue and provided an optimistic annual revenue forecast for the upcoming year.
CON SEC Filings - CONCENTRA GROUP HOLDINGS PAREN 10-K, 10-Q, 8-K Forms
This page provides access to the SEC filings for CONCENTRA GROUP HOLDINGS PAREN (Ticker: CON), a healthcare and occupational health services company. It includes 10-K, 10-Q, 8-K forms, detailing financial results, M&A activities such as the Nova Medical Centers and Pivot Onsite Innovations acquisitions, dividend declarations, and governance changes. The platform offers AI-powered summaries and real-time updates for investors to easily track key company information.
Concentra Group Holdings Parent Inc. (CON) Releases Q4 2025 Earnings: Revenue Growth and EPS Beat
Concentra Group Holdings Parent Inc. (CON) reported strong Q4 2025 earnings, exceeding revenue and EPS estimates with substantial year-over-year growth. Revenue reached $539.1 million, up 15.9%, and diluted EPS hit $0.27, a 125% increase. The company also saw significant movements in institutional holdings and congressional stock trading, while analysts maintain "Overweight" ratings with a median price target of $31.0.
A Glimpse of Concentra Group Holdings's Earnings Potential
Concentra Group Holdings (NYSE: CON) is scheduled to release its quarterly earnings report on Thursday, February 26, 2026, with analysts estimating an EPS of $0.26. The company has shown positive past earnings performance, beating estimates in the last quarter, which led to a 3.37% increase in share price. Financially, Concentra Group Holdings demonstrates strong profitability and asset utilization with impressive net margins and ROE, despite a high debt-to-equity ratio and market capitalization below industry benchmarks.
Concentra Group Holdings Parent, Inc. $CON Stock Holdings Increased by JPMorgan Chase & Co.
JPMorgan Chase & Co. significantly increased its stake in Concentra Group Holdings Parent (NYSE:CON) by 13.0% in Q3, bringing its total holdings to 3,874,283 shares valued at approximately $81.1 million. Other institutional investors like Thrivent Financial, Norges Bank, and Tributary Capital also increased or established new positions in the company. Concentra (NYSE: CON) is a Canada-based financial services holding company focused on serving Canadian credit unions.
How Strong Q4 Results And Georgia Expansion At Concentra (CON) Has Changed Its Investment Story
Concentra Group Holdings Parent (CON) recently announced strong Q4 preliminary results and expanded its U.S. footprint by opening a new occupational health medical center in Georgia. This reinforces the company's focus on employer-focused health services and network growth. While these developments support a positive investment narrative, investors should also consider factors like elevated G&A costs and leverage.
Wall Street Analysts Are Bullish on Top Healthcare Picks
Wall Street analysts are showing bullish sentiment towards the healthcare sector, specifically highlighting Community Health (CYH) and Perspective Therapeutics (CATX). Analysts from RBC Capital have maintained Buy ratings on both stocks, with price targets indicating potential upside. Community Health has a consensus Hold rating, while Perspective Therapeutics holds a Strong Buy consensus.
RBC Cites Stable Business Model For Concentra Group Holdings Parent, Inc. (CON) Amid Macroeconomic Volatility
RBC Capital has raised its price target for Concentra Group Holdings Parent, Inc. (CON) to $31 from $30, maintaining an Outperform rating due to the company's stable business model despite macroeconomic volatility and strong Q4 performance. The company, a leading U.S. occupational health services provider, anticipates FY2026 revenue between $2.25 billion and $2.35 billion and is expanding with a new medical center in Georgia. RBC highlighted CON's Q4 pre-announcement as above consensus and its early projection for FY2026.
RBC Cites Stable Business Model For Concentra Group Holdings Parent, Inc. (CON) Amid Macroeconomic Volatility
RBC Capital has reaffirmed its Outperform rating and raised its price target for Concentra Group Holdings Parent, Inc. (CON) to $31 from $30. This adjustment follows CON's strong Q4 performance and initial FY2026 projections, which indicate a stable business model despite macroeconomic volatility. Concentra plans to expand its operational footprint by opening a new medical center in Georgia and anticipates FY2026 revenue between $2.25 billion and $2.35 billion.
Concentra Group Holdings (CON): Analyst Ratings Signal 21% Upside In Healthcare Stock
Concentra Group Holdings (CON) is presented as an attractive investment in the healthcare sector, particularly for occupational health services. The company shows strong financial performance with high revenue growth and return on equity, and a sustainable dividend policy. Positive analyst sentiment indicates a potential upside of over 21% for the stock.
Concentra Group Holdings Parent, Inc. (NYSE:CON) Receives Consensus Rating of "Moderate Buy" from Brokerages
Concentra Group Holdings Parent, Inc. (NYSE:CON) has received a consensus "Moderate Buy" rating from five analysts, with an average 12-month price target of $29.00. Recent upgrades include RBC boosting its target to $31.00, and institutional investors like Barrow Hanley and Woodline Partners have significantly increased their stakes. The company, which specializes in financial services for Canadian credit unions, currently trades at $23.17 with a market capitalization of $2.97 billion.
Concentra Group stock hits 52-week high at 24.05 USD By Investing.com
Concentra Group Holdings Parent Inc.'s stock reached a new 52-week high of $24.05, representing a 6.62% increase over the past year, indicating strong investor confidence and market position. The company also reported exceeding its 2025 financial guidance with $2.16 billion in revenue and $431.9 million in adjusted EBITDA, alongside expanding its occupational health center footprint into Tucker, Georgia, and Hialeah, Florida. These developments highlight the company's growth and expansion in the occupational health services sector.
Concentra Group stock hits 52-week high at 24.05 USD
Concentra Group Holdings Parent Inc.'s stock reached a 52-week high of 24.05 USD, reflecting a 6.62% increase over the past year and indicating strong investor confidence. This milestone follows the company exceeding its 2025 financial guidance with $2.16 billion in revenue and expanding its operational footprint with new occupational health centers in Georgia and Florida. These developments highlight Concentra's growth trajectory and expanding presence in the occupational health services sector.
Concentra Group Holdings Parent (NYSE:CON) Sets New 12-Month High - What's Next?
Concentra Group Holdings Parent (NYSE:CON) reached a new 52-week high of $24.26, closing at $24.13 on robust trading volume. Analyst sentiment is generally positive, with a "Moderate Buy" consensus and a target price of $29.00, supported by recent upgrades and an increased price target from RBC. Institutional investment has also surged, notably with a significant new stake from Norges Bank and increased holdings by other major investors.
Concentra Group stock hits 52-week high at 24.05 USD By Investing.com
Concentra Group's stock reached a new 52-week high of $24.05, reflecting a 6.62% increase over the past year and indicating strong investor confidence. This performance follows the company's report of exceeding its full-year 2025 guidance with $2.16 billion in revenue and $431.9 million in adjusted EBITDA, alongside the expansion of its occupational health services with new centers in Georgia and Florida.
Concentra Group Holdings (CON): Analyzing A 23% Upside Potential In Healthcare
Concentra Group Holdings (CON) is presented as a strong player in the healthcare sector, specifically in occupational health services, with a market capitalization of $2.97 billion. The company shows robust financial health, including substantial revenue growth, high return on equity, and efficient management, indicated by a forward P/E ratio of 15.73 and strong cash flow. Analysts are highly positive, with all 7 ratings being "buy" and an average target price suggesting a 23.47% upside potential, making it an attractive investment for growth-focused investors.
Concentra Group Holdings Parent (CON) Is Up 8.9% After 2026 Guidance And Completed Share Buyback – What's Changed
Concentra Group Holdings Parent (CON) saw its shares rise 8.9% following the release of its 2026 guidance, which forecasts revenue between US$2.25–US$2.35 billion and net income of US$182–US$197 million. The company also completed a US$22.4 million share repurchase and opened a new occupational health center, signaling a focus on both operational growth and capital return. While these updates sharpen earnings expectations and tighten share count, the article notes existing risks such as high leverage and board structure.
Concentra Group Holdings Parent (NYSE:CON) Price Target Raised to $31.00 at Royal Bank Of Canada
Royal Bank of Canada has raised its price target for Concentra Group Holdings Parent (NYSE:CON) to $31.00 from $30.00, maintaining an "outperform" rating. This new target suggests a potential upside of approximately 39.89% from the stock's previous close. The company recently reported strong earnings, beating EPS expectations and showing a 17% year-over-year revenue increase.
Thrivent Financial for Lutherans Has $67.93 Million Holdings in Concentra Group Holdings Parent, Inc. $CON
Thrivent Financial for Lutherans significantly increased its stake in Concentra Group Holdings Parent, Inc. (NYSE:CON) by 41.1% in Q3, now holding 3,245,778 shares valued at approximately $67.93 million. This represents about 2.53% of the company. Concentra recently outperformed Q3 earnings expectations, reporting an EPS of $0.39 and revenue of $572.8 million, and maintains a "Moderate Buy" consensus rating from analysts with an average price target of $28.00.
RBC Lifts Price Target on Concentra Group Holdings Parent to $31 From $30, Keeps Outperform Rating
RBC has increased its price target for Concentra Group Holdings Parent (CON) to $31 from $30, while maintaining an Outperform rating. This update comes as Concentra announced its preliminary 2025 financial results and provided earnings guidance for 2026, alongside news of expanding its medical centers and appointing a new chief data officer.
Concentra releases preliminary 2025 results, provides 2026 guidance
The article from MSN states that Concentra has released its preliminary financial results for the year 2025. Additionally, the company has provided guidance for its financial expectations for the upcoming year 2026.
Should Stronger‑Than‑Guided 2025 Results and New 2026 Outlook Require Action From Concentra (CON) Investors?
Concentra Group Holdings Parent, Inc. (CON) recently reported 2025 preliminary results that surpassed guidance and issued a new 2026 revenue outlook of US$2.25 billion to US$2.35 billion. The company also completed a US$22.4 million share repurchase and expanded its network with a new occupational health center. These developments reinforce Concentra's investment narrative as a focused occupational health platform, though risks like debt, profit margins, and board inexperience remain.
Should Stronger‑Than‑Guided 2025 Results and New 2026 Outlook Require Action From Concentra (CON) Investors?
Concentra Group Holdings Parent, Inc. recently exceeded its 2025 guidance and issued a positive 2026 revenue outlook, along with a share repurchase and new clinic opening. While these actions reinforce the company's investment narrative of a focused occupational health platform with steady cash generation, key risks remain, including high debt and softer profit margins. Investors should consider these factors and multiple fair value estimates before making investment decisions.
Analysts Are Bullish on Top Healthcare Stocks: Concentra Group Holdings Parent, Inc. (CON), Neurocrine (NBIX)
Two healthcare stocks, Concentra Group Holdings Parent, Inc. (CON) and Neurocrine (NBIX), have received bullish sentiments from analysts. Bank of America Securities reiterated a Buy rating on CON with a $27.00 price target, while Citi maintained a Buy rating on NBIX with a $203.00 price target. Both companies are seen to have significant upside potential according to analyst consensus.
Should Stronger‑Than‑Guided 2025 Results and New 2026 Outlook Require Action From Concentra (CON) Investors?
Concentra Group Holdings Parent, Inc. recently exceeded its 2025 guidance and issued a new 2026 revenue outlook of US$2.25 billion to US$2.35 billion, alongside a US$22.4 million share repurchase and the opening of a new occupational health center. These developments reinforce the company's investment narrative of a focused occupational health platform with steady cash generation, despite risks like heavy debt and softer profit margins. While the shares might still be trading above fair value, these actions offer investors a clearer view of management's confidence and operational scale.
Concentra Announces Preliminary 2025 Financial Results, Provides 2026 Financial Guidance, and Announces Q4 2025 Earnings Call Date
Concentra Group Holdings Parent, Inc. (NYSE: CON) released preliminary unaudited financial results for Q4 and full year 2025, exceeding previous guidance, and provided its preliminary 2026 business outlook. The company reported significant revenue and Adjusted EBITDA growth for 2025, driven by an increased number of locations and patient visits. Concentra also announced its Q4 and full year 2025 earnings call on February 27, 2026, and published an Investor Book detailing its business and industry.
New Tucker clinic offers work injury care, drug tests, telemedicine
Concentra, a leader in occupational medicine, has opened a new medical center in Tucker, Georgia, expanding its presence in the region. The new facility will offer comprehensive occupational health services including work injury care, physical therapy, drug testing, and telemedicine for minor injuries. This expansion aims to enhance access to quality healthcare for employers and workers in DeKalb County.
Concentra Expands to Tucker, Georgia
Concentra, a national leader in occupational medicine, has opened a new medical center in Tucker, Georgia, located at 4434 Hugh Howell Road. This expansion aims to provide comprehensive occupational health services, including work injury care, physical therapy, and drug testing, to employers and workers in DeKalb County. The new facility will also offer telemedicine services through Concentra Telemed®, further strengthening Concentra's presence in Georgia.
Concentra Group Holdings Parent (NYSE:CON) Hasn't Managed To Accelerate Its Returns
Concentra Group Holdings Parent (NYSE: CON) shows decent returns on capital employed (ROCE) at 13%, which is close to the healthcare industry average. The company has maintained this ROCE while reinvesting 24% more capital into its operations over the past two years. While these consistent returns are positive, the stock has not delivered significant growth in total shareholder returns recently, suggesting investors might need to look deeper into its fundamentals.
